Simple blood test could spare prostate cancer patients from repeat biopsies
NCT ID NCT04052048
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a non-invasive blood test that looks at RNA patterns to see if a man's prostate cancer is becoming more aggressive. It involves 2,000 men on active surveillance for low-risk prostate cancer. The goal is to see if the blood test can reliably detect dangerous changes, potentially reducing the need for repeated invasive biopsies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Subtraction Normalized Expression of Phagocytes Blood Test (a non-invasive blood test that analyzes RNA to detect aggressive prostate cancer)
- What this could lead to
- If successful, this blood test could help men with low-risk prostate cancer avoid unnecessary repeat biopsies by accurately detecting if their cancer becomes more aggressive.
- What could go wrong
- This is an observational registry study, not a treatment trial. The test is still being validated, and it may not be accurate enough to replace biopsies in all cases.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INDOLENT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Comprehensive Urology
RECRUITINGRoyal Oak, Michigan, 48197, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.